Literature DB >> 6224800

Phorbol ester and mitogens stimulate human fibroblast secretions of plasmin-activatable plasminogen activator and protease nexin, an antiactivator/antiplasmin.

D L Eaton, J B Baker.   

Abstract

Tumor-promoting phorbol esters have been reported to greatly increase plasminogen activator (PA) activity produced in numerous cell types. Many of these studies have employed a widely used fibrinolysis assay for PA activity that involves large-scale dilution of cell lysates or conditioned medium (CM) into buffer containing plasminogen and the plasmin substrate 125I-fibrin. This assay indicates that phorbol ester and the mitogens epidermal growth factor (EGF) and thrombin all stimulate secretion of PA activity in our human foreskin fibroblast cultures. However, these effects are not observed in a modified fibrinolysis assay employing undiluted conditioned culture medium unless the medium is first treated at pH 3, which inactivates the secreted protease inhibitor, protease nexin (PN). Moreover, a direct assay for plasminogen activator activity based on cleavage of 125I-plasminogen indicates that conditioned culture medium contains little if any active plasminogen activator either before or after treatment of the cultures with phorbol ester or EGF. Phorbol ester and mitogens do stimulate secretion of (a) an inactive PA that can be activated by plasmin and (b) PN, which inhibits both the activated form of the PA and plasmin. Secretions of the inactive PA and PN are further correlated in that release of both is stimulated most by phorbol ester, somewhat less by EGF, and least by thrombin. Significantly, these effects are not accompanied by increases in total protein secretion. We propose that fibroblasts secrete PA in an inactive form in the presence of PN to confine PA activity to an as yet undefined location or event.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6224800      PMCID: PMC2112539          DOI: 10.1083/jcb.97.2.323

Source DB:  PubMed          Journal:  J Cell Biol        ISSN: 0021-9525            Impact factor:   10.539


  34 in total

1.  Comparison of the esterase activities of trypsin, plasmin, and thrombin on guanidinobenzoate esters. Titration of the enzymes.

Authors:  T Chase; E Shaw
Journal:  Biochemistry       Date:  1969-05       Impact factor: 3.162

2.  The reliability of molecular weight determinations by dodecyl sulfate-polyacrylamide gel electrophoresis.

Authors:  K Weber; M Osborn
Journal:  J Biol Chem       Date:  1969-08-25       Impact factor: 5.157

3.  Dexamethasone inhibition and phorbol myristate acetate stimulation of plasminogen activator in human embryonic lung cells.

Authors:  S Jaken; C Geffen; P H Black
Journal:  Biochem Biophys Res Commun       Date:  1981-03-31       Impact factor: 3.575

4.  Regulation of extracellular plasminogen activator by human fibroblasts. The role of protease nexin.

Authors:  R W Scott; D L Eaton; N Duran; J B Baker
Journal:  J Biol Chem       Date:  1983-04-10       Impact factor: 5.157

5.  A proenzyme form of human urokinase.

Authors:  T C Wun; L Ossowski; E Reich
Journal:  J Biol Chem       Date:  1982-06-25       Impact factor: 5.157

6.  The cellular target for the plasminogen activator, urokinase, in human fibroblasts - 66 000 dalton protein.

Authors:  J Keski-Oja; A Vaheri
Journal:  Biochim Biophys Acta       Date:  1982-04-29

7.  Inhibition of plasminogen activator release from transformed chicken fibroblasts by a protease inhibitor.

Authors:  J O'Donnell-Tormey; J P Quigley
Journal:  Cell       Date:  1981-11       Impact factor: 41.582

8.  Expression of the catalytic activity of plasminogen activator under physiologic conditions.

Authors:  J Aggeler; J Risch; Z Werb
Journal:  Biochim Biophys Acta       Date:  1981-06-11

9.  Correlation between a specific molecular weight form of plasminogen activator and metabolic activity of 3T3 cells.

Authors:  S Jaken; P H Black
Journal:  J Cell Biol       Date:  1981-09       Impact factor: 10.539

10.  Regulation of plasminogen activator in 3T3 cells: effect of phorbol myristate acetate on subcellular distribution and molecular weight.

Authors:  S Jaken; P H Black
Journal:  J Cell Biol       Date:  1981-09       Impact factor: 10.539

View more
  11 in total

1.  Transforming growth factor-ßs as modulators of pericellular proteolytic events.

Authors:  J Keski-Oja; J Lohi; M Laiho
Journal:  Cytotechnology       Date:  1989-12       Impact factor: 2.058

2.  Type beta transforming growth factor and epidermal growth factor suppress the plasminogen activator activity in a human glioblastoma cell line.

Authors:  E Helseth; A Dalen; G Unsgaard; R Vik
Journal:  J Neurooncol       Date:  1988-11       Impact factor: 4.130

3.  Cellular and extracellular plasminogen activator and inhibitor in an experimental tumour.

Authors:  Q Dong; M H Zhou; V Subbarao; C H Ts'ao
Journal:  Br J Exp Pathol       Date:  1988-10

4.  Tumor promoter PMA stimulates the synthesis and secretion of mouse pro-urokinase in MSV-transformed 3T3 cells: this is mediated by an increase in urokinase mRNA content.

Authors:  D Belin; F Godeau; J D Vassalli
Journal:  EMBO J       Date:  1984-08       Impact factor: 11.598

5.  Protease-nexin I as an androgen-dependent secretory product of the murine seminal vesicle.

Authors:  J D Vassalli; J Huarte; D Bosco; A P Sappino; N Sappino; A Velardi; A Wohlwend; H Ernø; D Monard; D Belin
Journal:  EMBO J       Date:  1993-05       Impact factor: 11.598

6.  Regulation of the synthesis and activity of urokinase plasminogen activator in A549 human lung carcinoma cells by transforming growth factor-beta.

Authors:  J Keski-Oja; F Blasi; E B Leof; H L Moses
Journal:  J Cell Biol       Date:  1988-02       Impact factor: 10.539

7.  Increase in urokinase plasminogen activator mRNA synthesis in human carcinoma cells is a primary effect of the potent tumor promoter, phorbol myristate acetate.

Authors:  M P Stoppelli; P Verde; G Grimaldi; E K Locatelli; F Blasi
Journal:  J Cell Biol       Date:  1986-04       Impact factor: 10.539

8.  Three types of human lung tumour cell lines can be distinguished according to surface expression of endogenous urokinase and their capacity to bind exogenous urokinase.

Authors:  R Schwartz-Albiez; H H Heidtmann; D Wolf; V Schirrmacher; G Moldenhauer
Journal:  Br J Cancer       Date:  1992-01       Impact factor: 7.640

9.  Enhanced production and extracellular deposition of the endothelial-type plasminogen activator inhibitor in cultured human lung fibroblasts by transforming growth factor-beta.

Authors:  M Laiho; O Saksela; P A Andreasen; J Keski-Oja
Journal:  J Cell Biol       Date:  1986-12       Impact factor: 10.539

10.  Association of a plasminogen activator inhibitor (PAI-1) with the growth substratum and membrane of human endothelial cells.

Authors:  E G Levin; L Santell
Journal:  J Cell Biol       Date:  1987-12       Impact factor: 10.539

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.